GLP-1

Type: Keyphrase
Name: GLP-1
First reported 10 hours ago - Updated 4 hours ago - 2 reports

BI and Zealand enter second peptide pact

Boehringer Ingelheim and Zealand Pharma have signed a pact to develop novel medicines for improved treatment of cardio-metabolic diseases.The global exclusive licence, research and development collaboration covers a novel therapeutic peptide project from ... [Published Pharma Times - 4 hours ago]
First reported 15 hours ago - Updated 15 hours ago - 1 reports

Green-Plant Membranes Cut Urge for Tasty Food, Spur Weight Loss

Reuters Health InformationBy Anne HardingJuly 28, 2014NEW YORK (Reuters Health) - Eating green plant membranes every day can help people lose weight by reducing their urge for palatable food, a new study in 38 women suggests.Those who consumed 5 grams ... [Published American Journal of Public Health - 15 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

Protein Drugs Market: Pharmaceutical Industry 2019

The pharmaceutical industry is witnessing a shift in focus from molecular drugs to protein based drugs due to its high specificity, enhanced efficacy, affinity, solubility, and low incidences of toxicity. The market for protein drugs is segmented into ... [Published MyNewsDesk - 16 hours ago]
First reported Jul 27 2014 - Updated Jul 27 2014 - 1 reports

*Whey protein could help diabetics*

Consuming whey protein – a popular protein among sportsmen who want to build muscle – before a regular breakfast reduces the blood sugar “spikes” common after meals rich in carbohydrates.It also is believed by Israeli and other researchers in an Israeli-Swedish ... [Published Jerusalem Post - Jul 27 2014]
Entities: Protein, GLP-1, Insulin, Fitness
First reported Jul 25 2014 - Updated Jul 26 2014 - 1 reports

This Week in the Endocrine Journals

(MedPage Today) -- Studies making an impact in endocrinology this week: variation in GLP-1 assays, gut flora as triggers of inflammation. ... [Published MedPageToday.com - medical news plus CME for ph ... - Jul 25 2014]
Entities: GLP-1, Endocrinology, Assay
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Novo Nordisk gains CHMP backing for Tresiba, Victoza combination therapy for diabetes

Novo Nordisk announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xultophy (insulin degludec/liraglutide) for the treatment of type 2 diabetes mellitus in adults. The company noted ... [Published FirstWord Pharma - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Novo's blockbuster diabetes combo nears EU approval

A committee of European Medicines Agency advisers is recommending approval for Novo Nordisk's ($NVO) combination of a long-acting insulin and its blockbuster GLP-1 drug Victoza, setting the stage for a near-term approval of what's expected to be the diabetes ... [Published FierceBiotech - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 1 reports

Whey Protein Consumption Helps With Blood Glucose Control In Diabetics By Promoting Insulin Response

PRWebWhey protein is an increasingly common dietary supplement consumed by sports enthusiasts and athletes to aid muscle repair and growth. Until now, whey protein has had a rather limited consumer market. However, groundbreaking scientific research has ... [Published Myrtle Beach Sun News - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Once-Weekly Dulaglutide Is Noninferior to Daily Liraglutide

The investigational once-weekly dulaglutide (Eli Lilly) is noninferior to once-daily liraglutide ( Victoza , Novo Nordisk), providing similar glycated hemoglobin (HbA 1c ) reductions, in adults with type 2 diabetes poorly controlled with metformin, a ... [Published American Journal of Public Health - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Lilly’s GLP-1 Agonist Trulicity Shows Promising Results in Trials

We’ve been following the development of Lilly’s Trulicity (dulaglutide), a once-weekly GLP-1 receptor agonist , for almost two years now, so it was encouraging to hear an update on the drug at ADA last month. Results from recent trials presented at ADA ... [Published diaTribe - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

New SGLT Drugs Coming

SGLT1 and 2 are proteins that move glucose out of the intestines and kidneys. Blocking them might keep glucose in the intestines and cause more glucose to be urinated out via the kidneys, lowering blood sugar levels. That’s what “SGLT inhibitor” drugs ... [Published Diabetes Self-Management - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Oral GLP-1 formulations

The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared ... [Published Free Patents Online - Jul 22 2014]

Quotes

The new deal "reflects the confidence both parties have in each other and of their complimentary expertise in the researchresearch and development of new medicines" the firms said in a statement
...and, over time, intensify insulin therapy in order to keep glucose levels under control," said Dr Klaus Henning Jensen, Medical Director, UK. "Currently, to intensify their treatment, these patients have the option to increase the dose of basal insulin or add other injectables. Some patients are reluctant to step up their treatment as raising the insulin dose may in turn increase their risk of hypoglycaemia and weight gain – and most of these intensified treatments require more than one injection a day."
...and important one," noted Michel Pairet, Boehringer Ingelheim's senior vice president, corporate division R&D non-clinical, in a statement. "We are, therefore, extremely pleased to enter into this new agreement with Zealand, a company recognised as experts in their field, which will further complement and strengthen our own discovery and development efforts in the area of cardio-metabolic diseases."
...3%) after 12 weeks was comparable to the effect of treatment with the GLP-1 analogue liraglutide," Dr. Erlanson-Albertsson and her team note. "Thus increasing the endogenous release of GLP-1 may be as efficient for obesity treatment as pharmacological agents. It is very likely however that treatment with green-plant membranes involves other additional mechanisms for body weight reduction."

More Content

All (161) | News (129) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (1) | Press Releases (3)
sort by: Date | Relevance
BI and Zealand enter second peptide pact [Published Pharma Times - 4 hours ago]
CHMP positive opinion for Xultophy? [Published Hospital Pharmacy Europe - 5 hours ago]
Zealand inks a $402M cardio-metabolic peptide p... [Published FierceBiotech - 10 hours ago]
Boehringer Ingelheim, Zealand Expand Peptide Pa... [Published Genetic Engineering News - 11 hours ago]
Zealand and Boehringer link up to advance novel... [Published Pharma Letter - 12 hours ago]
Green-Plant Membranes Cut Urge for Tasty Food, ... [Published American Journal of Public Health - 15 hours ago]
Protein Drugs Market: Pharmaceutical Industry 2019 [Published MyNewsDesk - 16 hours ago]
Exercise, Hunger, and Energy Intake [Published General Medicine eJournal - 22 hours ago]
Potential of Acarbose to Reduce Cardiovascular ... [Published Theheart.org - 22 hours ago]
*Whey protein could help diabetics* [Published Jerusalem Post - Jul 27 2014]
West End library digitally preserving yearbooks [Published Pocono Record - Jul 25 2014]
This Week in the Endocrine Journals [Published MedPageToday.com - medical news plus CME for ph ... - Jul 25 2014]
Novo's blockbuster diabetes combo nears EU appr... [Published FierceBiotech - Jul 25 2014]
Novo Nordisk gains CHMP backing for Tresiba, Vi... [Published FirstWord Pharma - Jul 25 2014]
Eli Lilly's (LLY) CEO John Lechleiter on Q2 201... [Published Seeking Alpha - Jul 25 2014]
Library digitally preserving yearbooks [Published Pocono Record - Jul 25 2014]
Once-Weekly Dulaglutide Is Noninferior to Daily... [Published American Journal of Public Health - Jul 24 2014]
Whey Protein Consumption Helps With Blood Gluco... [Published Myrtle Beach Sun News - Jul 24 2014]
Lilly’s GLP-1 Agonist Trulicity Shows Promising... [Published diaTribe - Jul 24 2014]
What Do We Want Out of Our Diabetes Treatments? [Published diaTribe - Jul 24 2014]
New SGLT Drugs Coming [Published Diabetes Self-Management - Jul 24 2014]
MannKind : Patent Issued for Diketopiperazine M... [Published 4 Traders - Jul 23 2014]
Market Research Report On : Diabetes Devices Dr... [Published MyNewsDesk - Jul 22 2014]
Oral GLP-1 formulations [Published Free Patents Online - Jul 22 2014]
5 More Possible Partners For MannKind's Afrezza... [Published Seeking Alpha - Jul 21 2014]
Which foods are best bought in farmers markets ... [Published Examiner.com - Jul 21 2014]
Can hulled barley help to normalize your blood ... [Published Examiner.com - Jul 21 2014]
The Human GLP-1 Analogs Liraglutide and Semaglu... [Published Diabetes - Jul 19 2014]
Simultaneous GLP-1 and Insulin Administration A... [Published Diabetes Care - Jul 19 2014]
Whey Protein to Prevent After-Meal Blood Sugar ... [Published Diabetes Self-Management - Jul 18 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
This Week in the Endocrine Journals [Published MedPageToday.com - medical news plus CME for ph ... - Jul 25 2014]
(MedPage Today) -- Studies making an impact in endocrinology this week: variation in GLP-1 assays, gut flora as triggers of inflammation. ...
9 Signs You Need to Eat More Fat [Published Mark's Daily Apple - Jul 17 2014]
By now, we all basically agree that fat is an essential nutrient . Certain fats, like linoleic acid and alpha linolenic acid, are physiologically essential because our bodies cannot produce them. Other fats, like those found in extra virgin olive ...
[Comment] Which incretin-based therapy for type... [Published The Lancet online - Jul 11 2014]
Incretin-based therapies, either incretin enhancers (eg, dipeptidyl peptidase-4 [DPP-4] inhibitors such as gliptins) or incretin mimetics (eg, glucagon-like peptide-1 [GLP-1] receptor agonists) are increasingly used for treatment of type 2 diabetes mellitus, ...
Flamel Technologies Announces Positive Preclini... [Published Marketwire - Breaking News Releases - Jun 25 2014]
LYON, FRANCE--(Marketwired - Jun 25, 2014) - Flamel Technologies (NASDAQ: FLML) today announced that its once weekly formulation of exenatide, based on its Medusa drug delivery platform, has been successfully tested in minipigs. Exenatide is a glucagon-like ...
ADA: Weekly GLP-1 Agonist Matches Daily Victoza... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 17 2014]
SAN FRANCISCO (MedPage Today) -- The investigational weekly GLP-1 agonist dulaglutide improved glycemic control in type 2 diabetes comparably to daily liraglutide (Victoza) but with less weight loss, researchers reported here. ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Zealand provides summary of new clinical data a... [Published GlobeNewswire: Advertising News - Jun 17 2014]
Zealand presented new data on two novel peptide... [Published GlobeNewswire: Acquisitions News - Jun 17 2014]
Presentation of several Zealand peptide therape... [Published GlobeNewswire: Advertising News - Jun 10 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.